Drug Trial Radar · NCT06469853
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients
Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Feb 1, 2024
Primary completion
Dec 4, 2024
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- Medibiofarma S.L.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-015 oral treatment during 28 days in Huntington's Disease patients on top of standard of care.
Conditions
- Huntington Disease
Interventions
MBF-015 16 mg oral capsulesDrug
MBF-015 oral capsules HDAC inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 43 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.